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Problems of screening for psychiatric
comorbidity in the medically Ill: What
can be recommended?
A. Diefenbacher
Evangelisches Krankenhaus Königin Elisab, Berlin, Germany
CL-psychiatrists have to work under severe time pressure in acute
care setting. Hence, it is necessary to have an armamentarium of
screening tools for disorders most frequently met in the general
hospital. This presentation will discuss such tools for delirium,
alcohol abuse, depression, personality disorders (“how to manage
difﬁcult patients”), attachment styles. On a conceptual level, the
so-called “situational approach” in cl-psychiatry will be discussed.
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∗ Corresponding author.
Introduction Lifetime prevalence of psychiatric comorbidity in
neurological patients is as high as 55%, but it remains often
undetected and therefore untreated in hospital settings. Further,
clinicians tend to make little use of the consultative and liaison
psychiatric team for detection and treatment of anxiety and mood
disorders in neurological patients. The current study aimed to
investigate whether the implementation of a stepped screening
protocol with high risk feedback to the clinician had an inﬂuence
on the use of consultative and liaison psychiatric services.
Method All patients admitted to the neurological ward were
assessed using a stepped screening protocol for depression, anxiety
and substance use during 15 months. Positive screening resulted
in feedback to the clinicians depending on the study phase (e.g.
feedback vs. no feedback).
Results No differences were found in the use of consultative and
liaison psychiatric services during the non-feedback and feedback
phase.
Conclusion Screening and high risk feedback of psychiatric
comorbidity in neurological patients does not increase psychiatric
referral rates. It points to the necessity of a more integrated col-
laborative care model for detection and treatment of psychiatric
comorbidity.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
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Background Inﬂammatory mediators may be relevant to explain
the frequent comorbidity between depression, neurocognitive dis-
orders and HIV. HIV induces activation of inﬂammatory mediators,
mainly cytokines, that have been involved in the onset of depres-
sion and response to antidepressant treatment.
Aim To identify recurring proﬁles of inﬂammatory biomarkers
subtending depression, effectiveness of antidepressants and neu-
rocognitive disorders among HIV-infected individuals.
Methods All adult newly HIV-diagnosed out-patients attending
HIV clinics in three towns ofNorthern Italywere screened, assessed
for depressionand studied immunologically and forneurocognitive
disorders.
Results Twenty-ﬁve patients have been enrolled so far: of these,
35% were positive to PHQ-9 screening, of which 6 were positive to
the diagnostic assessment for depression. No neurocognitive disor-
ders were found among the patients. As the project will develop, it
http://dx.doi.org/
0924-9338/
S54 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S53–S68
is expected that frequency of depression, neurocognitive disorders
and effective antidepressant treatment will be found to correlate
to the proﬁle of immune biomarkers. These ﬁndings might help to
understand the etiology of depression in HIV, and speciﬁcally the
role of inﬂammation and immunological changes.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2017.01.026
W004
Psychosocial screening of alcohol liver
disease patients before liver
transplantation
D. Telles-correia
Faculty of Medicine, University of Lisbon, Psychiatry, Lisbon, Portugal
In Europe, 30% to 50% of liver transplantations are currently due
to alcoholic liver disease (ALD). In the United States, this per-
centage is 17.2%. Post-transplant survival and other predictors
of clinical course do not differ signiﬁcantly from those in other
types of transplanted patients, as long as there is no relapse of
drinking. However, 20%–25% of these patients lapse or relapse to
heavydrinkingpost-operatively,whichhasbeenassociatedwithan
increased risk of liver damage and mortality. It is therefore crucial
to design speciﬁc selection and follow-up strategies aimed at this
particular type of patient. Several good and poor prognosis factors
that could help to predict a relapse have been suggested, among
them the duration of abstinence, social support, a family history
of alcoholism, abuse diagnosis versus alcohol dependence, non-
acceptance of diagnosis related to alcohol use, presence of severe
mental illness, non-adherence in a broad sense, number of years
of alcoholism, and daily quantity of alcohol consumption. In this
article, we discuss these and other, more controversial factors in
selecting ALD patients for liver transplantation. Abstinence should
be themain goal after transplantation in anALDpatient. In this arti-
cle, we review the several deﬁnitions of post-transplant relapse, its
monitoring and thepsychopharmacological andpsychotherapeutic
treatment.
Disclosure of interest The author has not supplied his declaration
of competing interest.
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The current status of women in
psychiatry in Europe
S. Frangou
Icahn School of Medicine at Mount Sinai, Psychiatry, New York, USA
For more than two decades, psychiatry has retained its position
amongst the medical specialties with the highest proportion of
women entering residency programs. The percentage of women
in junior academic positions in psychiatry is also high and consis-
tently higher than that of men. However, the number of women
in positions of leadership remains disproportionally low at around
5% with no evidence of improvement over time. The phenomenon
of female under-representation is not unique to psychiatry or
academia. Women are under-represented in all ﬁelds of leadership
and this is a matter of wider societal concern. In this presentation,
I will discuss external and internal barriers that women face and
detail positiveactions that canhelpwomensucceed in their careers.
Disclosure of interest The author has edited and co-authored a
book on “Women in Academic Psychiatry: A mind to Succeed”
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Barriers to gender equality in career
advancement and leadership
D. Wasserman
Karolinska Institute, Stockholm, Sweden
Life as a researcher includes a large amount of competition and
a heavy workload. Professor’s tasks comprise, besides their own
research, to lead your research team, to have the responsibility
for higher education, expertise in diverse contexts, review of sci-
entiﬁc articles, to seek ﬁnancial support, to work with national
and international committees, to serve in administrative posts at
the university and in international associations, to write articles,
books and book chapters, to attend meetings and conferences, and
to address the many other tasks that may arise throughout one’s
career. This makes one dependent on skillful co-workers, which
should not be taken for granted. Given the constant ﬂow of incom-
ing requests, onehas to think and choosebefore agreeing to commit
to a task at hand, in order to not set aside your own research. This
demands a high capability to prioritize. The choice of a life partner
who can share both professional and private interests, a partner
whounderstands, encourages and supports, while at the same time
gives the necessary critical feedback, is a treasure. Freud said “love
and work are the cornerstones of our humanness”, but work must
be pleasurable thus try to combine work, love, and play.
Disclosure of interest The author has not supplied his declaration
of competing interest.
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Background Attention deﬁcit/hyperactivity disorder (ADHD) is
an important contributing factor in the pathophysiology of sub-
stance use disorders (SUD), and ADHD occurs more often in
populations with SUD compared to the general population. This
high prevalence rate and comorbidity may relate to a shared neu-
robiological vulnerability, including a deregulation of the brain’s
dopamine system. This comorbidity directly impacts the treat-
ment of ADHD: treatment with methylphenidate is less effective in
patients with ADHD and SUD compared to ADHD patients without
SUD.
Methods We investigate the underlying neurobiological back-
ground of reduced treatment effectiveness for adult ADHDpatients
with comorbid SUD.
Results We observed lower available dopamine transporters, as
well as a reducedbindingofmethylphenidate to these transporters,
andmoreneurocognitive dysfunction in adults ADHDpatientswith
SUD compared to ADHD patients without SUD.
Conclusion Comorbid ADHD and SUD has a high prevalence
rate and reduces ADHD treatment effectiveness, which makes
it necessary to screen for the presence of ADHD in patients
